DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

Michael Razavi; Ying-Ying Wei; Xiao-Quan Rao; Ji-Xin Zhong

doi:10.1186/s40779-022-00410-2

Your Location：

Home >

Browse articles >

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

REVIEW | Updated：2023-05-10

- DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
- DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
- Military Medical Research 2023年10卷第2期页码：227-241
- Affiliations：
  
  1.Tulane University School of Medicine, New Orleans, LA 70112, USA
  2.Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430032, China
  3.Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430032, China
  4.Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430032, China
- Author bio：
  
  * xqrao@tjh.tjmu.edu.cn;
  zhongjixin620@163.com
- Funds：
  
  the National Natural Science Foundation of China(81974254;31870906;82170470)
- DOI：10.1186/s40779-022-00410-2
  中图分类号：
- 纸质出版：2023-04
- Accepted：
Scan QR Code
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits[J]. Military Medical Research, 2023,10(2):227-241.

Cite this article as: Razavi M, Wei YY, Rao XQ, Zhong JX. DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Mil Med Res. 2022;9(1):45.
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits[J]. Military Medical Research, 2023,10(2):227-241. DOI： 10.1186/s40779-022-00410-2.

Cite this article as: Razavi M, Wei YY, Rao XQ, Zhong JX. DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Mil Med Res. 2022;9(1):45. DOI： 10.1186/s40779-022-00410-2.

摘要

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM

the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints. As a result

since 2008

the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. The present review article strives to assess the safety and benefits of incretin-based therapy

a new class of antidiabetic drug

on the health of patient cardiovascular systems. In the process

this review will also provide a physiological overview of the incretin system and how key components function in T2DM.

关键词

Keywords

references

Rao Kondapally Seshasai S , Kaptoge S , Thompson A , Di Angelantonio E , Gao P , Sarwar N , et al . Diabetes mellitus, fasting glucose, and risk of cause-specific death . N Engl J Med. 2011 ; 364 ( 9 ): 829 – 41 .

Brown A , McArdle P , Taplin J , Unwin D , Unwin J , Deakin T , et al . Dietary strategies for remission of type 2 diabetes: a narrative review . J Hum Nutr Diet. 2021 ; 35 ( 1 ): 165 – 78 .

Magkos F , Hjorth MF , Astrup A . Diet and exercise in the prevention and treatment of type 2 diabetes mellitus . Nat Rev Endocrinol. 2020 ; 16 ( 10 ): 545 – 55 .

Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HA . 10-year followup of intensive glucose control in type 2 diabetes . N Engl J Med. 2008 ; 359 ( 15 ): 1577 – 89 .

ADVANCE Collaborative Group , Patel A , MacMahon S , Chalmers J , Neal B , Billot L , et al . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes . N Engl J Med. 2008 ; 358 ( 24 ): 2560 – 72 .

Gerstein HC , Miller ME , Byington RP , Goff DC Jr , Bigger JT , et al . Effects of intensive glucose lowering in type 2 diabetes . N Engl J Med. 2008 ; 358 ( 24 ): 2545 – 59 .

Low Wang CC , Everett BM , Burman KD , Wilson PWF . Cardiovascular safety trials for all new diabetes mellitus drugs? Circulation. 2019 ; 139 ( 14 ): 1741 – 3 .

Ferro EG , Michos ED , Bhatt DL , Lincoff AM , Elshazly MB . New decade, new FDA guidance for diabetes drug development: lessons learned and future directions . J Am Coll Cardiol. 2020 ; 76 ( 21 ): 2522 – 6 .

Waldrop G , Zhong J , Peters M , Goud A , Chen YH , Davis SN , et al . Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis . J Diabetes Complic. 2018 ; 32 ( 1 ): 113 – 22 .

Lovshin JA , Drucker DJ . Incretin-based therapies for type 2 diabetes mellitus . Nat Rev Endocrinol. 2009 ; 5 ( 5 ): 262 – 9 .

Müller TD , Finan B , Bloom SR , D’Alessio D , Drucker DJ , Flatt PR , et al . Glucagon-like peptide 1 (GLP-1) . Mol Metab. 2019 ; 30 : 72 – 130 .

McLean BA , Wong CK , Campbell JE , Hodson DJ , Trapp S , Drucker DJ . Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation . Endocr Rev. 2021 ; 42 ( 2 ): 101 – 32 .

Andersen A , Lund A , Knop FK , Vilsboll T . Glucagon-like peptide 1 in health and disease . Nat Rev Endocrinol. 2018 ; 14 ( 7 ): 390 – 403 .

Larsen PJ , Holst JJ . Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter . Regul Pept. 2005 ; 128 ( 2 ): 97 – 107 .

Zhou M , Mok MT , Sun H , Chan AW , Huang Y , Cheng AS , et al . The antidiabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis . Oncogene. 2017 ; 36 ( 29 ): 4135 – 49 .

Webb DL , Abrahamsson N , Sundbom M , Hellstrom PM . Bariatric surgery – time to replace with GLP-1? Scand J Gastroenterol. 2017 ; 52 ( 6–7 ): 635 – 40 .

Waldrop G , Zhong J , Peters M , Rajagopalan S . Incretin-based therapy for diabetes: what a cardiologist needs to know . J Am Coll Cardiol. 2016 ; 67 ( 12 ): 1488 – 96 .

Ast J , Arvaniti A , Fine NHF , Nasteska D , Ashford FB , Stamataki Z , et al . Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics . Nat Commun. 2020 ; 11 ( 1 ): 467 .

Hutch CR , Sandoval D . The role of GLP-1 in the metabolic success of bariatric surgery . Endocrinology. 2017 ; 158 ( 12 ): 4139 – 51 .

Patel V , Joharapurkar A , Dhanesha N , Kshirsagar S , Patel K , Bahekar R , et al . Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice . Can J Physiol Pharmacol. 2013 ; 91 ( 12 ): 1009 – 15 .

Taher J , Baker CL , Cuizon C , Masoudpour H , Zhang R , Farr S , et al . GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance . Mol Metab. 2014 ; 3 ( 9 ): 823 – 33 .

Jastreboff AM , Aronne LJ , Ahmad NN , Wharton S , Connery L , Alves B , et al . Tirzepatide once weekly for the treatment of obesity . N Engl J Med. 2022 ; 387 ( 3 ): 205 – 16 .

Hernández C , Bogdanov P , Corraliza L , Garcia-Ramirez M , Sola-Adell C , Arranz JA , et al . Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes . Diabetes. 2016 ; 65 ( 1 ): 172 – 87 .

Steven S , Jurk K , Kopp M , Kroller-Schon S , Mikhed Y , Schwierczek K , et al . Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice . Br J Pharmacol. 2017 ; 174 ( 12 ): 1620 – 32 .

Wang D , Luo P , Wang Y , Li W , Wang C , Sun D , et al . Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism . Diabetes. 2013 ; 62 ( 5 ): 1697 – 708 .

Berglund LM , Lyssenko V , Ladenvall C , Kotova O , Edsfeldt A , Pilgaard K , et al . Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via endothelin-1 and CREB . Diabetes. 2016 ; 65 ( 1 ): 239 – 54 .

Scrocchi LA , Brown TJ , MaClusky N , Brubaker PL , Auerbach AB , Joyner AL , et al . Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene . Nat Med. 1996 ; 2 ( 11 ): 1254 – 8 .

Toft-Nielson M , Madsbad S , Holst JJ . The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones . Diabetes. 1996 ; 45 ( 5 ): 552 – 6 .

Chen BD , Zhao WC , Dong JD , Sima H . Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues . Mol Biol Rep. 2014 ; 41 ( 7 ): 4313 – 20 .

Nauck MA , Siemsglüss J , Orskov C , Holst JJ . Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections . Z Gastroenterol. 1996 ; 34 ( 3 ): 159 – 66 .

Ussher JR , Drucker DJ . Cardiovascular biology of the incretin system . Endocr Rev. 2012 ; 33 ( 2 ): 187 – 215 .

Zhong J , Rao X , Deiuliis J , Braunstein Z , Narula V , Hazey J , et al . A potential role for dendritic cell/macrophage-expressing dpp4 in obesityinduced visceral inflammation . Diabetes. 2013 ; 62 ( 1 ): 149 – 57 .

Gros R , You X , Baggio LL , Kabir MG , Sadi AM , Mungrue IN , et al . Cardiac function in mice lacking the glucagon-like peptide-1 receptor . Endocrinology. 2003 ; 144 ( 6 ): 2242 – 52 .

Zhong J , Gong Q , Goud A , Srinivasamaharaj S , Rajagopalan S . Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials . J Diabetes Res. 2015 ; 2015 : 606031 .

Bengsch B , Seigel B , Flecken T , Wolanski J , Blum HE , Thimme R . Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26) . J Immunol. 2012 ; 188 ( 11 ): 5438 – 47 .

Rao X , Zhao S , Braunstein Z , Mao H , Razavi M , Duan L , et al . Oxidized ldl upregulates macrophage dpp4 expression via TLR4/TRIF/CD36 pathways . EBioMedicine. 2019 ; 41 : 50 – 61 .

Bruzzese L , Rostain JC , Née L , Condo J , Mottola G , Adjriou N , et al . Effect of hyperoxic and hyperbaric conditions on the adenosinergic pathway and CD26 expression in rat . J Appl Physiol. 2015 ; 119 ( 2 ): 140 – 7 . https://doi.org/10.1152/japplphysiol.00223.2015 https://doi.org/10.1152/japplphysiol.00223.2015 .

Zander M , Madsbad S , Madsen JL , Holst JJ . Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study . Lancet. 2002 ; 359 ( 9309 ): 824 – 30 .

Prasad-Reddy L , Isaacs D . A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond . Drugs Context. 2015 ; 4 : 212283 .

Gupta V . Glucagon-like peptide-1 analogues: an overview . Indian J Endocrinol Metab. 2013 ; 17 ( 3 ): 413 – 21 .

Saraiva FK , Sposito AC . Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists . Cardiovasc Diabetol. 2014 ; 13 : 142 .

Iacobellis G , Mohseni M , Bianco SD , Banga PK . Liraglutide causes large and rapid epicardial fat reduction . Obesity. 2017 ; 25 ( 2 ): 311 – 6 .

Helmstädter J , Keppeler K , Küster L , Munzel T , Daiber A , Steven S . Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-the role of the GLP-1 receptor . Br J Pharmacol. 2022 ; 179 ( 4 ): 659 – 76 .

Kumar S , Mittal A , Mittal A . A review upon medicinal perspective and designing rationale of DPP-4 inhibitors . Bioorg Med Chem. 2021 ; 46 : 116354 .

Ahrén B , Holst JJ , Mårtensson H , Balkan B . Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice . Eur J Pharmacol. 2000 ; 404 ( 1–2 ): 239 – 45 .

Chen XW , He ZX , Zhou ZW , Yang T , Zhang X , Yang YX , et al . Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus . Clin Exp Pharmacol Physiol. 2015 ; 42 ( 10 ): 999 – 1024 .

Green JB , Bethel MA , Armstrong PW , Buse JB , Engel SS , Garg J , et al . Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes . N Engl J Med. 2015 ; 373 ( 3 ): 232 – 42 .

White WB , Bakris GL , Bergenstal RM , Cannon CP , Cushman WC , Fleck P , et al . EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) . Am Heart J. 2011 ; 162 ( 4 ): 620-626.e1 .

Scirica BM , Bhatt DL , Braunwald E , Steg PG , Davidson J , Hirshberg B , et al . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus . N Engl J Med. 2013 ; 369 ( 14 ): 1317 – 26 .

Oyama J , Murohara T , Kitakaze M , Ishizu T , Sato Y , Kitagawa K , et al . The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial . PLoS Med. 2016 ; 13 ( 6 ): e1002051 .

de Boer SA , Heerspink HJL , Juárez Orozco LE , van Roon AM , Kamphuisen PW , Smit AJ , et al . Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE) . Diabetes Obes Metab. 2017 ; 19 ( 8 ): 1147 – 54 .

Nakamura T , Iwanaga Y , Miyaji Y , Nohara R , Ishimura T , Miyazaki S , et al . Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up . Cardiovasc Diabetol. 2016 ; 15 : 54 .

Marso SP , Bain SC , Consoli A , Eliaschewitz FG , Jodar E , Leiter LA , et al . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes . N Engl J Med. 2016 ; 375 ( 19 ): 1834 – 44 .

Marso SP , Daniels GH , Brown-Frandsen K , Kristensen P , Mann JF , Nauck MA , et al . Liraglutide and cardiovascular outcomes in type 2 diabetes . N Engl J Med. 2016 ; 375 ( 4 ): 311 – 22 .

Sattar N , Petrie MC , Zinman B , Januzzi JL Jr . Novel diabetes drugs and the cardiovascular specialist . J Am Coll Cardiol. 2017 ; 69 ( 21 ): 2646 – 56 .

Pfeffer MA , Claggett B , Diaz R , Dickstein K , Gerstein HC , Kober LV , et al . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome . N Engl J Med. 2015 ; 373 ( 23 ): 2247 – 57 .

Rosenstock J , Perkovic V , Johansen OE , Cooper ME , Kahn SE , Marx N , et al . Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial . JAMA. 2019 ; 321 ( 1 ): 69 – 79 .

Rosenstock J , Kahn SE , Johansen OE , Zinman B , Espeland MA , Woerle HJ , et al . Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial . JAMA. 2019 ; 322 ( 12 ): 1155 – 66 .

Holman RR , Bethel MA , Mentz RJ , Thompson VP , Lokhnygina Y , Buse JB , et al . Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes . N Engl J Med. 2017 ; 377 ( 13 ): 1228 – 39 .

Hernandez AF , Green JB , Janmohamed S , D’Agostino RB Sr , Granger CB , Jones NP , et al . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial . Lancet. 2018 ; 392 ( 10157 ): 1519 – 29 .

Husain M , Birkenfeld AL , Donsmark M , Dungan K , Eliaschewitz FG , Franco DR , et al . Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes . N Engl J Med. 2019 ; 381 ( 9 ): 841 – 51 .

Gerstein HC , Colhoun HM , Dagenais GR , Diaz R , Lakshmanan M , Pais P , et al . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial . Lancet. 2019 ; 394 ( 10193 ): 121 – 30 .

Gerstein HC , Sattar N , Rosenstock J , Ramasundarahettige C , Pratley R , Lopes RD , et al . Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes . N Engl J Med. 2021 ; 385 ( 10 ): 896 – 907 .

Ferdinand KC , Botros FT , Atisso CM , Sager PT . Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified metaanalysis of prospectively adjudicated cardiovascular events . Cardiovasc Diabetol. 2016 ; 15 : 38 .

Simó R , Guerci B , Schernthaner G , Gallwitz B , Rosas-Guzman J , Dotta F , et al . Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study . Cardiovasc Diabetol. 2015 ; 14 : 116 .

Courrèges JP , Vilsbøll T , Zdravkovic M , Le-Thi T , Krarup T , Schmitz O , et al . Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes . Diabet Med. 2008 ; 25 ( 9 ): 1129 – 31 .

Shih CJ , Chen HT , Kuo SC , Ou SM , Chen YT . Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in elderly patients with type 2 diabetes: a nationwide study . J Am Med Dir Assoc. 2016 ; 17 ( 1 ): 59 – 64 .

Ryan D , Acosta A . GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond . Obesity (Silver Spring). 2015 ; 23 ( 6 ): 1119 – 29 .

Giugliano D , Scappaticcio L , Longo M , Caruso P , Maiorino MI , Bellastella G , et al . GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs . Cardiovasc Diabetol. 2021 ; 20 ( 1 ): 189 .

Xia L , Shen T , Dong W , Su F , Wang J , Wang Q , et al . Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis . Diabetes Res Clin Pract. 2021 ; 177 : 108904 .

Longato E , Di Camillo B , Sparacino G , Tramontan L , Avogaro A , Fadini GP . Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes . Eur J Prev Cardiol. 2021 ; 28 ( 1 ): 22 – 9 . https://doi.org/10.1093/eurjpc/zwaa081 https://doi.org/10.1093/eurjpc/zwaa081 .

Gutzwiller JP , Tschopp S , Bock A , Zehnder CE , Huber AR , Kreyenbuehl M , et al . Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men . J Clin Endocrinol Metab. 2004 ; 89 ( 6 ): 3055 – 61 .

McCormick LM , Heck PM , Ring LS , Kydd AC , Clarke SJ , Hoole SP , et al . Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus . Cardiovasc Diabetol. 2015 ; 14 : 102 .

Gaspari T , Welungoda I , Widdop RE , Simpson RW , Dear AE . The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE –/– mouse model . Diab Vasc Dis Res. 2013 ; 10 ( 4 ): 353 – 60 .

Giugliano D , Longo M , Signoriello S , Maiorino MI , Solerte B , Chiodini P , et al . The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs . Cardiovasc Diabetol. 2022 ; 21 ( 1 ): 42 .

Chen JJ , Wu CY , Jenq CC , Lee TH , Tsai CY , Tu HT , et al . Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease . JAMA Netw Open. 2022 ; 5 ( 3 ): e221169 .

Fang M , Wang D , Coresh J , Selvin E . Trends in Diabetes treatment and control in U.S. Adults, 1999–2018 . N Engl J Med. 2021 ; 384 ( 23 ): 2219 – 28 .

Terasaki M , Nagashima M , Nohtomi K , Kohashi K , Tomoyasu M , Sinmura K , et al . Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice . PLoS ONE. 2013 ; 8 ( 8 ): e70933 .

Shah Z , Kampfrath T , Deiuliis JA , Zhong J , Pineda C , Ying Z , et al . Longterm dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis . Circulation. 2011 ; 124 ( 21 ): 2338 – 49 .

Zeng Y , Li C , Guan M , Zheng Z , Li J , Xu W , et al . The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms . Cardiovasc Diabetol. 2014 ; 13 : 32 .

Nozue T , Fukui K , Koyama Y , Fujii H , Kunishima T , Hikita H , et al . Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study . Am J Cardiovasc Dis. 2016 ; 6 ( 4 ): 153 – 62 .

Sun F , Wu S , Guo S , Yu K , Yang Z , Li L , et al . Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network metaanalysis . Diabetes Res Clin Pract. 2015 ; 110 ( 1 ): 26 – 37 .

Avgerinos I , Michailidis T , Liakos A , Karagiannis T , Matthews DR , Tsapas A , et al . Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis . Diabetes Obes Metab. 2020 ; 22 ( 3 ): 335 – 45 .

Sun F , Shanshan W , Wang J , Guo S , Chai S , Yang Z , Li L , Zhang Y , Ji L , Zhan S . Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network metaanalysis . Clin Ther. 2015 ; 37 ( 1 ): 225-241.e8 .

Gejl M , Søndergaard HM , Stecher C , Bibby BM , Moller N , Botker HE , et al . Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes . J Clin Endocrinol Metab. 2012 ; 97 ( 7 ): E1165 – 9 .

Witteles RM , Keu KV , Quon A , Tavana H , Fowler MB . Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy . J Card Fail. 2012 ; 18 ( 10 ): 804 – 9 .

Ban K , Noyan-Ashraf MH , Hoefer J , Bolz SS , Drucker DJ , Husain M . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways . Circulation. 2008 ; 117 ( 18 ): 2340 – 50 .

Zhao T , Parikh P , Bhashyam S , Bolukoglu H , Poornima I , Shen YT , et al . Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts . J Pharmacol Exp Ther. 2006 ; 317 ( 3 ): 1106 – 13 .

Scheen AJ . GLP-1 receptor agonists and heart failure in diabetes . Diabetes Metab. 2017 ; 43 ( Suppl 1 ): 2S13 .

Margulies KB , Hernandez AF , Redfield MM , Givertz MM , Oliveira GH , Cole R , et al . Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial . JAMA. 2016 ; 316 ( 5 ): 500 – 8 .

Jorsal A , Kistorp C , Holmager P , Tougaard RS , Nielsen R , Hanselmann A , et al . Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial . Eur J Heart Fail. 2017 ; 19 ( 1 ): 69 – 77 .

Arturi F , Succurro E , Miceli S , Cloro C , Ruffo M , Maio R , et al . Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure . Endocrine. 2017 ; 57 ( 3 ): 464 – 73 .

Chen WR , Hu SY , Chen YD , Zhang Y , Qian G , Wang J , et al . Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention . Am Heart J. 2015 ; 170 ( 5 ): 845 – 54 .

Huang M , Wei R , Wang Y , Su T , Li Q , Yang X , et al . Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials . Ann Med. 2017 ; 49 ( 7 ): 552 – 61 .

Liang B , Gu N . Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE . Cardiovasc Diabetol. 2020 ; 19 ( 1 ): 106 .

Zinman B , Wanner C , Lachin JM , Fitchett D , Bluhmki E , Hantel S , et al . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes . N Engl J Med. 2015 ; 373 ( 22 ): 2117 – 28 .

Vanderheyden M , Bartunek J , Goethals M , Verstreken S , Lambeir AM , De Meester I , et al . Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside . Clin Chem Lab Med. 2009 ; 47 ( 3 ): 248 – 52 .

Lourenço P , Silva S , Cunha F , Pereira J , Ribeiro A , Silva N , et al . Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction . Int J Cardiol. 2017 ; 241 : 249 – 54 .

Lourenço P , Friões F , Silva N , Guimaraes JT , Bettencourt P . Dipeptidyl peptidase IV and mortality after an acute heart failure episode . J Cardiovasc Pharmacol. 2013 ; 62 ( 2 ): 138 – 42 .

Kankanala SR , Syed R , Gong Q , Ren B , Rao X , Zhong J . Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure . Am J Transl Res. 2016 ; 8 ( 5 ): 2450 – 8 .

Verma S , Goldenberg RM , Bhatt DL , Farkouh ME , Quan A , Teoh H , et al . Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis . CMAJ Open. 2017 ; 5 ( 1 ): E152 – 77 .

Li L , Li S , Deng K , Liu J , Vandvik PO , Zhao P , et al . Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies . BMJ. 2016 ; 352 : i610 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据